Johns Hopkins Medicine is currently seeking participants for a groundbreaking clinical trial investigating the potential effects of psilocybin, the psychoactive compound found in “magic mushrooms”, on adults diagnosed with ADHD.
Dried psilocybin mushrooms.
The study, led by Principal Investigator Roland Griffiths, PhD, is open to individuals aged 18-65 who meet the criteria for ADHD.
This research aims to explore whether psilocybin can provide therapeutic benefits for those struggling with ADHD, a condition often characterized by inattention, hyperactivity, and impulsiveness. Psilocybin has garnered significant attention in recent years for its potential to treat various mental health conditions, including depression and anxiety. This study represents one of the first efforts to examine its effects on ADHD.
Participation in the trial is confidential, and there are no costs associated with enrolling. The research team emphasizes that all applicants and participants’ privacy will be strictly maintained. The study will assess the psychological impact of psilocybin and whether it may offer a novel approach to managing ADHD symptoms.
Individuals interested in participating in the study are encouraged to visit the official website at www.hopkinspsychedelic.org/anorexia or contact the research team directly at hopkinsanorexiastudy@jhmi.edu or 410-550-2253. This trial provides a unique opportunity to contribute to the evolving understanding of how psychedelics may be used in treating mental health disorders.
Johns Hopkins has been at the forefront of psychedelic research, and this study continues its tradition of exploring innovative treatments that could potentially transform mental health care.
More articles from The Marijuana Herald can be found below.
